Mesenchymal Stem Cells (MSC)

Mesenchymal stem cells, sometimes now called mesenchymal stromal cells in the scientific literature, are multipotent adult stem cells isolated from bone marrow, adipose (fat) tissue, or umbilical cord tissue [1]. Multipotent means they can differentiate into a limited set of related cell types: bone, cartilage, and fat cells, primarily. This is a much smaller repertoire than the pluripotent embryonic or induced pluripotent stem cells covered elsewhere in this section, which can in principle form nearly any cell type.

MSCs are the most commercially used stem cell type worldwide, appearing in everything from knee injection clinics to intravenous longevity infusions [1]. That commercial dominance is not matched by regulatory approval. As of mid-2026, MSC-derived products hold exactly one active full approval anywhere in the world: none currently. Alofisel (darvadstrocel), an adipose-derived allogeneic MSC product approved by the European Medicines Agency in March 2018 for complex perianal fistulas in Crohn's disease, was voluntarily withdrawn from the EU market by Takeda in December 2024 for commercial reasons unrelated to safety findings [2]. No MSC product has ever received full FDA approval in the United States.

The central scientific question about MSCs is mechanism: how, if at all, do they work? Early hypothesis held that transplanted MSCs would engraft into damaged tissue and differentiate to replace lost cells. That model has mostly been abandoned. Tracking studies show that intravenously infused MSCs rarely persist at the target site for more than a few days to weeks, and engraftment rates are low [3]. The dominant current explanation is paracrine signaling: MSCs sense their environment and secrete a mix of growth factors, cytokines, and extracellular vesicles that recruit the body's own repair systems and dial down inflammation, rather than becoming new tissue themselves [1][3].

The molecular toolkit behind this signaling includes interleukin-10 and TGF-beta, both of which suppress T-cell proliferation and dampen immune attack on damaged tissue [4][5]. MSCs also release exosomes, small membrane-bound vesicles that carry microRNA, proteins, and other signaling cargo between cells. Reviews of MSC-derived exosomes in cardiac repair describe specific microRNA transfers, for example miR-19a acting on the SOX6 pathway to protect heart muscle cells after ischemic injury [3][6]. This exosome and microRNA-based signaling model explains why some studies report benefit from MSC-derived exosome products alone, without any live cells, including in skin rejuvenation trials discussed on our skin and cosmetic evidence pages.

Because MSCs act as biological signal generators more than as replacement parts, their effects tend to be modest, variable across studies, and hard to distinguish from strong placebo or contextual effects in conditions with a large subjective component, most clearly demonstrated in knee osteoarthritis research (see our dedicated osteoarthritis page). A 2021 meta-analysis pooling 62 randomized trials and 3,546 participants across roughly 20 disease categories found MSC administration was not associated with serious adverse events like death or infection, but was linked to transient fever, fatigue, constipation, and sleeplessness at higher rates than control groups [7]. Thromboembolism risk from intravenous MSC infusion, tied to the cells' natural tissue factor expression, is a recognized but generally low-frequency safety concern that has prompted specific dosing and monitoring recommendations [8][9].

Clinically, the most advanced MSC programs today target conditions where inflammation plays a large role and where a modest, transient functional gain is meaningful: aging-related frailty, mild Alzheimer's disease, Crohn's fistulas, and knee osteoarthritis. Longeveron's laromestrocel (Lomecel-B), a bone-marrow-derived allogeneic MSC product, has produced the most statistically robust MSC trial data to date in frailty and Alzheimer's disease, detailed on their respective pages in this section [10][11]. None of these programs has yet converted trial success into full US or EU approval.

For consumers evaluating a marketed MSC product, the practical takeaway is that biological plausibility does not equal proof of clinical benefit. MSCs have a real, well-documented mechanism of action. Whether that mechanism produces a benefit large enough to matter, and durable enough to justify cost and infusion risk, is a question this encyclopedia answers separately for each condition rather than for the cell type as a whole.

A new COVIDMES randomized pilot trial adds a useful negative result to this safety and efficacy picture. Torres and colleagues enrolled 26 hospitalized patients with moderate-to-severe COVID-19 ARDS; 25 received two intravenous doses of Wharton’s Jelly-derived MSCs or placebo [12]. The product was well tolerated and produced no treatment-related serious adverse events. It did not improve 28-day mortality, mechanical-ventilation duration, or ICU stay. Ferritin declined more over time with MSCs, but the biomarker change was not associated with clinical improvement [12]. The result supports feasibility and short-term safety in this narrow setting, not efficacy. It should not be generalized to frailty, osteoarthritis, Alzheimer’s disease, or commercial anti-aging infusions. It also reinforces the page’s central distinction between biomarker movement and patient-important outcomes.